CP 2569

Drug Profile

CP 2569

Alternative Names: TNCA

Latest Information Update: 16 Sep 2005

Price : $50

At a glance

  • Originator Colgate-Palmolive
  • Developer Colgate-Palmolive; MacroChem
  • Class Antineoplastics; Osteoporosis therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypercalcaemia; Osteitis deformans; Postmenopausal osteoporosis

Most Recent Events

  • 01 Sep 2005 Discontinued - Preclinical for Hypercalcaemia in USA (unspecified route)
  • 01 Sep 2005 Discontinued - Preclinical for Postmenopausal osteoporosis in USA (unspecified route)
  • 01 Sep 2005 Discontinued - Preclinical for Osteitis deformans in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top